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Abstract 
Background: Between 2009 and 2012, malaria cases diagnosed in a Médecins sans Frontières programme have 
increased fivefold in Baraka, South Kivu, Democratic Republic of the Congo (DRC). The cause of this increase is not 
known. An in vivo drug efficacy trial was conducted to determine whether increased treatment failure rates may have 
contributed to the apparent increase in malaria diagnoses.
Methods: In an open-randomized non-inferiority trial, the efficacy of artesunate–amodiaquine (ASAQ) was com-
pared to artemether–lumefantrine (AL) for the treatment of uncomplicated falciparum malaria in 288 children aged 
6–59 months. Included children had directly supervised treatment and were then followed for 42 days with weekly 
clinical and parasitological evaluations. The blood samples of children found to have recurring parasitaemia within 
42 days were checked by PCR to confirm whether or not this was due to reinfection or recrudescence (i.e. treatment 
failure).
Results: Out of 873 children screened, 585 (67 %) were excluded and 288 children were randomized to either ASAQ 
or AL. At day 42 of follow up, the treatment efficacy of ASAQ was 78 % before and 95 % after PCR correction for re-
infections. In the AL-arm, treatment efficacy was 84 % before and 99.0 % after PCR correction. Treatment efficacy after 
PCR correction was within the margin of non-inferiority as set for this study. Fewer children in the AL arm reported 
adverse reactions.
Conclusions: ASAQ is still effective as a treatment for uncomplicated malaria in Baraka, South Kivu, DRC. In this 
region, AL may have higher efficacy but additional trials are required to draw this conclusion with confidence. The 
high re-infection rate in South-Kivu indicates intense malaria transmission.
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Background
The Democratic Republic of Congo (DRC) is one of the 
five countries with the highest malaria burden in the 
world [1]. The eastern part of DRC is suffering from 
armed conflict and internal political instability. The 
conflict has caused massive suffering for civilians, with 
estimates of millions of deaths, directly or indirectly, as 
a result of the fighting [2, 3]. In this humanitarian cri-
sis there are acute health needs, with limited access to 
humanitarian assistance and violations of basic rights 
and freedoms. A survey conducted in 2014 in South Kivu 
indicated a crude mortality rate (CMR) of 2.80 per 10,000 
per day [95 % CI (2.40–3.28)] and an under-five mortality 
rate (<5MR) of 5.58 per 10,000 per day [95 % CI (4.60–
6.76)]. Both of these mortality rates are more than two 
times above the emergency threshold [4].
Médecins sans Frontières–Operational Centre Amster-
dam (MSF-OCA or MSF) has been working in the 
provinces of North Kivu and South Kivu since the early 
1990s and in Katanga since 2003 (Fig. 1). In South Kivu, 
MSF supports primary and secondary health care in the 
Baraka and Kimbi hospitals and in six health centres, and 
provides response to outbreaks and emergencies.
Malaria is holo-endemic in most of DRC, with seasonal 
fluctuations in transmission intensity in the east and south 
of the country. Plasmodium falciparum is the predominant 
species causing malaria in DRC [5]. Since 2003, MSF has 
introduced artemisinin-based combination therapy (ACT) 
in all programmes worldwide. Artesunate–amodiaquine 
(ASAQ) has been the first-line treatment for uncomplicated 
malaria in DRC since 2005. Artemether–lumefantrine (AL) 
is the second line treatment for uncomplicated malaria [6, 
7]. Targeted distribution of long-lasting insecticide-treated 
bed nets (LLIN) to pregnant women and children hospital-
ized for severe malaria has been ongoing since 2003 in the 
MSF Baraka programme. The last mass LLIN distribution 
in this health zone was carried out in 2012.
Since 2009, MSF has seen an apparent rise in malaria 
incidence in most programmes in DRC. The National 
Malaria Control Programme (Programme National de 
Lutte contre le Paludisme, PNLP) has also observed an 
increase in malaria cases. In the Baraka programme, 
without any significant changes to the programme activi-
ties, the number of parasitologically confirmed uncompli-
cated malaria cases has risen from 7457 in 2009 to 44,317 
cases in 2012 (Fig. 2). In order to investigate whether the 
Fig. 1 Map of the Democratic Republic of Congo
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observed increase in malaria over the years was associ-
ated with increased treatment failure rates, the efficacy of 
the first-line treatment, ASAQ was evaluated, and com-
pared to that of AL in children aged 6–59 months with 
confirmed uncomplicated falciparum malaria.
Methods
Study design and site
An open-randomized non-inferiority trial comparing 
the efficacy of ASAQ to that of AL for the treatment of 
uncomplicated malaria, in children aged between six and 
59  months, was conducted following the World Health 
Organization (WHO) protocols for surveillance of anti-
malarial drug efficacy [8]. The study was carried out 
between October 2013 and December 2014 in the outpa-
tient clinic of Baraka General Hospital and in the Health 
Centre of Baraka in South Kivu, DRC.
Ethical considerations
The study was approved by the Ethical Review Board 
(ERB) of MSF on June 17th 2013 and by the Zone Chief 
Medical Officer (Médecin Chef de Zone) and the Pro-
vincial Medical Inspector (Médecin Inspecteur Proven-
çal MIP) of South Kivu (N251/969/B.MIP/SK/2013). 
It was registered at ClinicalTrials.gov under num-
ber NCT02741024. Eligible patients were included in 
the study after an adult parent/caretaker gave written 
informed consent. If the parent/caretaker was illiterate, a 
literate witness was asked to sign next to the parent/care-
taker’s fingerprint. Free health care for malaria and other 
illnesses is provided by MSF to the general population 
and was, therefore, also provided throughout the study 
follow-up period to all patients included in the study.
Study population
Children aged between 6 and 59 months, presenting with 
fever (axillary temperature  ≥37.5  °C) or reported his-
tory of fever in the last 24  h, and with a positive rapid 
diagnostic test (RDT) were enrolled in the study if they 
had: (1) a body weight ≥5 kg, (2) a slide confirmation of 
mono-infection with P. falciparum with an asexual para-
site density between 2000 and 200,000/µl of blood, (3) an 
ability to swallow (crushed or dissolved) oral medication, 
(4) a high probability of respecting follow up visits, and 
(5) a signed informed consent by their adult (≥18 years 
old) parent/caretaker. Children were excluded if they 
presented with general danger signs according to the 
WHO protocol “Methods for surveillance of antima-
larial drug efficacy” [8]. These included signs of severe/
complicated malaria, including severe anaemia (Hb <5 g/
dL), history of convulsions, and jaundice. Children were 
also excluded if they had severe acute malnutrition (indi-
cated by a weight-for-height Z score (WHZ) of <−3 Z, a 
middle upper arm circumference (MUAC) of  <115  cm, 
or bilateral oedema), a concomitant febrile or chronic ill-
ness, a known allergy to one of the study medications, or 
had received a full course of one of the artemisinin-based 
combinations under study in the previous 28 days.
Sample size
Sample size calculations were based on the data that was 
available before October 2012. At that moment, studies 
determined the 42-day risk of recurrent parasitaemia 
due to recrudescence (treatment failure) in children to 
range from 0.9 to 6 % with AL and ASAQ [9–12]. Based 
on a conservative estimated risk of recurrent parasitae-
mia (due to recrudescence, PCR corrected) of 5  %, 120 
patients per treatment arm would be needed to detect a 
difference in the risk of recrudescence between treatment 
arms of no greater than 7 % (one-sided type I error of 5, 
80 % power) [13]. In order to account for undetermined 
PCR results, loss to follow up, withdrawal, and protocol 
violations, the total estimated sample size was increased 
by 20 % to 288 patients (144 per arm).
Study procedure
All patients who were eligible for the study had a medi-
cal examination, and a MUAC and WHZ screening. A 
thick and a thin blood smear were performed and capil-
lary blood was collected on a fast technology for analysis 
(FTA) card (Whatmann, UK). If the patient was eligible, 
informed consent was requested from the parent/care-
taker after the explanation of the study by one of the 
study team members. Once the informed consent was 
obtained, patients were randomized to one of two treat-
ment regimens according to which treatment had been 
randomly pre-allocated to that unique patient number. 
Treatment regimens consisted of: (1) ASAQ fixed dose 
(Winthrop Sanofi Aventis), given as 1 tab/day over three 
days (≥5–  <  9  kg, 1 tab of 25  mg artesunate/67.5  mg 
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Fig. 2 Confirmed malaria cases in Baraka project 2009–2012, DRC
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amodiaquine base; ≥9–<18 kg, 50 mg artesunate/135 mg 
amodiaquine base), or (2) AL fixed combination (Coar-
tem®, 20 mg artemether/120 mg lumefantrine, Novartis) 
given with milk twice daily over three days (≥5– <15 kg, 1 
tab of 20 mg artemether/120 mg lumefantrine BD, ≥15–
<25  kg, 2 tabs of 20  mg artemether/120  mg lumefan-
trine BD with fatty food) over 3  days. Drugs were given 
according to the manufacturer’s instructions and dosage. 
Study medication was imported and stored under strict 
regulations, ensuring control within the provided stor-
age temperature and humidity ranges. The first dose of 
the study drug at day 0 (D0) was dispensed at the health 
clinic, and was taken by the child while under supervision 
of a study team member. For children who could not swal-
low tablets, AL tablets were dissolved, and ASAQ tablets 
were crushed in minimal amounts of water and dispensed 
with a spoon. After intake, the child was observed for 
30  min. If the child vomited or spat out the medication 
within the monitoring period, a resting period of 15 min 
was observed before re-administering a repeat dose. If 
the repeat dose was also vomited within 30 min, the child 
was administered a rescue treatment (which was defined 
as the alternative treatment that the child was not rand-
omized to) and was excluded from the study. Patients 
returned to the clinic on days 1 and 2 for observed admin-
istration of the study drug and a clinical assessment. In 
order to observe the intake of the evening doses of AL, 
patients randomized to receive AL were visited at home 
at around 8  h, 32  h and 56  h after the first dose. A fol-
low up was scheduled for all patients on day 3, 7, 14, 21, 
28, 35 and 42 for clinical assessment and blood smear 
evaluation.
If a clinical or parasitological treatment failure was 
observed, rescue treatment was initiated and a second 
blood sample was collected for PCR analysis. Caretak-
ers were advised to present the child to the clinic at any 
time in case of illness. Patients who failed to return for 
scheduled follow up visits were traced immediately by 
home-visitors to minimize loss to follow up. Adverse 
events were evaluated by a physician and recorded at 
each visit.
Treatment outcomes
Study endpoints were classified according to the WHO 
guidelines [8] as adequate clinical and parasitologi-
cal response (ACPR), early treatment failure (ETF), late 
clinical failure (LCF) and late parasitological failure 
(LPF). Patients who were lost to follow-up, who with-
drew their consent at any time before reaching a study 
endpoint, or who had a protocol violation (ex. wrongful 
inclusion by study staff, non-completion of full treatment 
course, administration of a study drug by a third-party, 
re-infection with a species other than P. falciparum) were 
not assigned an efficacy treatment outcome.
Laboratory techniques
Initial testing for malaria infection was done on fin-
ger-prick blood using an RDT, the SD Bioline 05FK50 
Malaria Ag P.f (Standard Diagnostics, Kyonggi, Republic 
of Korea). This RDT relies on detection of the Histidine 
Rich Protein 2 (HRP2), and is amongst the most sensitive 
according to the WHO product testing programme [14].
Thick and thin blood smears were stained with 10  % 
Giemsa for 15 min. Smears were read to 100 fields before 
they could be declared negative. Species were confirmed 
on the thin smear. Quantification of P. falciparum asexual 
parasitaemia on the thick smear was performed accord-
ing to the WHO protocol “Methods for surveillance of 
antimalarial drug efficacy” [8]. Presence or absence of P. 
falciparum gametocytes was recorded.
Each slide was read, independently, by two qualified 
microscopists in the Baraka hospital laboratory, Para-
site densities were calculated by taking a mean of the 
two counts. Blood smears with discordant results (differ-
ences in species diagnosis, in parasite density of >50 % or 
in the presence of parasites) were re-examined by a third 
microscopist who was blinded to the results of the first 
two, and parasite density was calculated by taking a mean 
of the two closest counts. In addition, external quality 
control of the slides was performed by blinded re-check-
ing of 50 randomly selected malaria slides by an expert 
microscopist at the Epicentre Mbarare Research Base in 
Uganda.
Haemoglobin levels on D0 or during follow-up were 
determined using the HemoCue® Hb 301 System (Äng-
elholm, Sweden), according to manufacturer’s instruc-
tions. PCR genotyping analysis was performed in order 
to distinguish true recrudescence (same parasite strain) 
from a newly acquired infection (different parasite strain) 
on capillary blood samples stored on FTA cards. The 
genotyping was performed at the Department of Medical 
Microbiology, at the Academic Medical Centre (Amster-
dam, The Netherlands. PCR amplification of template 
DNA and analysis of glurp, msp2 and msp1 alleles in pre- 
(enrolment) and post-treatment (failure) samples was 
performed according to the WHO protocol [15]. Pre- and 
post-treatment pairs with similar genotype were classi-
fied as recrudescence (true failure), and pairs with differ-
ent genotypes were classified as re-infection according to 
WHO protocol “Methods and techniques for clinical tri-
als on antimalarial drug efficacy: Genotyping to identify 
parasite populations” [15]. Species-specific PCRs were 
performed on samples with possible mixed re-infections 
according to Shokoples et al. [16].
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Data analysis
All data were double entered in the WHO global database 
for anti-malarial drug efficacy by two different epidemi-
ologists, as well as in the worldwide anti-malarial resist-
ance network (WWARN) database provided online [17]. 
Statistical analysis was performed using STATA version 
13.1. Data was analysed per-protocol and by intention-
to-treat. Kaplan–Meier survival curves were generated to 
determine the cumulative probability of recurrence-free 
survival over the 42  days follow-up. These probability 
estimates were compared using a log rank test. For the 
per-protocol analysis, patients who were lost to follow 
up or withdrawn were removed from the denominator. 
Patients were considered withdrawn from the PCR-cor-
rected analysis if the PCR results were unclassifiable or if 
the results of PCR indicated that the failure was due to a 
mono re-infection with a Plasmodium species other than 
the P. falciparum (such as Plasmodium vivax, Plasmo-
dium malariae or Plasmodium ovale).
Chi square tests or Fisher’s exact tests were used to 
compare categorical data and Student’s t test was used 
for continuous data, as appropriate. The log rank test was 
used to compare Kaplan–Meier survival curves. p < 0.05 
were considered statistically significant.
Availability of data and materials
Data are available on request in accordance with MSF’s 
data sharing policy [18].
Results
Study trial profile and baseline characteristics
A description of the study outline is shown in Fig. 3. Out 
of 873 children screened for uncomplicated malaria dur-
ing the study period, 585 (67.0  %) were excluded. The 
main reasons for exclusion were ACT intake in the last 
28  days (118, 20.2  %), parasitaemia outside the study 
range (116, 19.8 %) or co-morbidities such as pneumonia 
or urinary tract infections (86, 14.7 %). 288 children were 
included in the study and were randomized to receive 
ASAQ or AL. 18 children (6.3 %) in the ASAQ group and 
13 children (4.5 %) in the AL group did not complete the 
three days of allocated treatment, due to the following: 
developing (apparent) signs of severe malaria (n = 5 ETF, 
n = 3 wrongfully admitted to ward), a late realisation of 
wrongful enrolment (n = 10), having an observed treat-
ment dose missed (n = 7), vomiting of at least one of the 
treatment doses twice (n = 5), a dosage error (n = 1). Of 
the children who received their full course of supervised 
treatment (257), 19 children (7.0 %) did not reach an ana-
lysable end result (censored), either due to being lost to 
follow up (n = 8), having had an anti-malarial adminis-
tered by a 3rd party (n =  9), or having been re-infected 
with a malaria species other than P. falciparum (n = 2).
The baseline characteristics of the patients enrolled in 
the study are presented in Table  1. Boys and girls were 
equally represented in the study population, with an 
average age of 31.5 months [(32.2 months for ASAQ (IQR 
20.0–47.0) and 30.9 for AL (IQR 21.0–41.5)]. The average 
WHZ score was below international standards and simi-
lar in both treatment groups (–0.59 for ASAQ and −0.68 
for AL) [19]. The average axillary temperature at D0 was 
higher in the AL group (39.02 °C, IQR 38.0–39.7) than in 
the ASAQ group (38.77 °C, IQR 38.4–39.8). No other sta-
tistically significant differences were observed between 
baseline characteristics for children randomized in both 
treatment arms.
Treatment outcome results
Five children were classified as early treatment failures as 
per study protocol. All of these children had a parasito-
logical improvement, but had either anaemia or jaundice 
that warranted admission to the hospital. They received 
intravenous artesunate according to the study protocol 
and the WHO guidelines for the treatment of malaria 
[20] and were withdrawn from the study.
Treatment efficacy estimates are presented in Table  2 
for days 28 and day 42 after initiation of treatment. Before 
PCR genotyping, 23 (9.7  %) children (13/119 on ASAQ 
and 10/119 on AL) were classified as late clinical failure 
and 23 (9.7 %) children (14/119 on ASAQ and 9/119 on 
AL) as late parasitological failure on day 42. Furthermore, 
during the study period, two children who were on AL 
were re-infected with other species (P. ovale), as con-
firmed in weekly parasitological examinations; this was 
an involuntary protocol violation and these two children 
were censored in the final analysis. In total, 192 (80  %) 
children had an adequate clinical and parasitological 
response (92/119 for ASAQ and 100/119 for AL) at day 
42. The proportion of recurring infection (including the 
two reinfections with other species) during the 42  days 
follow-up was higher in the ASAQ group (27/119, 22.7 %) 
compared to the AL group (21/119, 17.6 %), but this dif-
ference was not statistically significant. Similarly, cumu-
lative failure on day 28 was not statistically significantly 
different between arms.
PCR genotyping to determine re‑infection 
and recrudescence
46 paired FTA filter paper samples were PCR genotyped, 
including all late clinical and parasitological failure sam-
ples. Following the PCR genotyping, 21 of the 27 recur-
rent parasitaemic episodes in the ASAQ arm (77.8  %) 
were classified as re-infections and 6 (22.2  %) as recru-
descence. In the AL arm, 15 out of 19 samples (78.9 %) 
were classified as re-infections and 1 as (5.3 %) as recru-
descence. There were no indications that treatment 
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dosing was lower for the children experiencing treatment 
failure.
For three samples with recurring parasitaemia in the 
AL arm outcome could not be classified by PCR; these 
samples were censored at the last date of follow-up for 
which the child was still malaria negative. The propor-
tions of children reaching each a study endpoint, before 
and after PCR adjustment, are presented in Table 2.
Kaplan–Meier survival curves
The cumulative probability of recurrence-free survival 
over the 42  days follow-up was determined by Kaplan–
Meier survival analysis. The PCR un-adjusted curves 
shown in Fig. 4 indicate a non-significantly higher prob-
ability of remaining free of recurrent parasitaemia in the 
AL arm compared to the ASAQ arm (p  =  0.16). After 
adjustment by PCR to distinguish between reinfection 
Trial profile
Assessed for eligibility (n=873)
Excluded (n=585)
♦ Not meeting inclusion criteria (n=503)
♦ Declined to participate (n=82)
♦ Analysed  (n=119)
♦ Censored from analysis (n=0)
♦ Completed 42 days follow up (n=119)
♦ Did not complete 42 days follow up (n=7)
Lost to follow-up (n=3)
Protocol violation before end of follow 
up (n=4)
Allocated to ASAQ (n=144)
♦ Completed allocated treatment (n=126)
♦ Did not complete allocated treatment (n=18)
4 with signs of severe malaria (D1)
5 protocol violations
5 vomiting
4 lost to follow up
♦ Completed 42 days follow up (n=121)
♦ Did not complete 42 days follow up (n=10)
Lost to follow-up (n=5)
Protocol violation before end of follow 
up (n=5)
Allocated to AL (n=144)
♦ Complete allocated treatment (n=131)
♦ Did not complete allocated treatment (n=13)
1 with signs of severe malaria (D1)
5 protocol violation
3 vomiting
4 lost to follow up
♦ Analysed  (n=119)
♦ Censored from analysis (n=2)
Re-infection other species (n=2)
Allocation
Analysis
Follow-Up
Randomized (n=288)
Enrollment
Fig. 3 Trial profile efficacy study ASAQ–AL, Baraka, DRC
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and recrudescence, the proportion of patients achieving 
ACPR at day 42 (treatment efficacy) was higher for the AL 
arm (99.0 %, 95CI 93.2–99.9) compared to the ASAQ arm 
(94.7 %, 95 CI 88.4–97.6), p = 0.0496 (Fig. 5). Regardless 
of the statistically significant differences between study 
arms, the difference in ACPR by day 42 after initiation of 
treatment was within the margin of non-inferiority.
Parasite clearance
A relatively large proportion (13.7 % on ASAQ, 20.0 % on 
AL) of children still had parasites on day 2 of follow-up. 
This proportion fell to below 5 % in both arms on day 3. 
There was no significant difference in the proportion of 
parasites at D2 and D3 between the two treatment arms 
(Table 3).
Table 1 Baseline characteristics of included patients
All data is presented as the mean with the interquartile range (IQR) in brackets, unless otherwise stated
ASAQ (n = 144) AL (n = 144) p value
Age, in months 32.2 (20.0–47.0) 30.9 (21.0–41.5) 0.412
# Male (%) 65 (79) 65 (79) 1.000
Weight for height Z-score −0.59 (−1.39 to 0.22) −0.68 (−1.40–0.08) 0.484
Temperature in  °C 38.8 (38.0–39.7) 39.02 (38.4–39.8) 0.049
Parasite density/µl at day 0 63,637 (15, 211–95, 962) 45,154 (14, 225–94, 746) 0.826
Log parasite density at day 0 10.5 (9.6–11.5) 10.4 (9.6–11.5) 0.935
Haemoglobin in g/dl at day 0 9.5 (8.5–10.8) 9.7 (8.7–10.8) 0.316
Table 2 Per-protocol crude/unadjusted and  PCR-adjusted study endpoints at  days 28 and  42 of  patient follow-up. 
Patients with re-infections and individuals for whom the outcome could not be assessed by PCR were censored from the 
PCR adjusted analysis
The analysis of the treatment outcomes by intention-to-treat are shown in Additional file 1: Annexure 1
Crude/no PCR Day 28 Day 42
ASAQ (n = 119) AL (n = 122) p value ASAQ  
(n = 119)
AL (n = 119) p value
n % n % n % n %
Late clinical failure 8 6.7 4 3.3 0.250 13 10.9 10 8.4 0.510
Late parasitological failure 10 8.4 6 4.9 0.277 14 11.8 9 7.6 0.273
Adequate clinical and parasitological response 101 84.9 112 91.8 0.093 92 77.3 100 84.0 0.189
Cumulative failure 18 15.1 10 8.2 0.093 27 22.7 19 16.0 0.189
PCR adjusted/corrected Day 28 Day 42
ASAQ (n = 105)  AL (n = 111) p value ASAQ (n = 98)  AL (n = 101) p value
n % n % n % n %
Late clinical failure (recrudescence) 1 1.0 0 0 0.486 1 1.0 1 1.0 1.000
Late parasitological failure (recrudenscence) 3 2.9 0 0 0.113 5 5.1 0 0 0.027
Adequate clinical and parasitological response 101 96.2 111 100 0.038 92 93.9 100 99.0 0.049
Cumulative failure 4 3.8 0 0 0.054 6 6.1 1 1.0 0.062
Fig. 4 Kaplan–Meier survival estimates PCR-unadjusted. Treatment 
efficacy for ASAQ and AL was 85.3 and 92.1 % at day 28 (p = 0.0933), 
and 77.7 and 84.5 % at day 42 (p = 0.1605), respectively
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Treatment safety
There were no serious adverse events during the period 
of the study. However, minor adverse events occurred in 
both treatment arms during the treatment period (days 
0–2). The adverse event most reported was asthenia 
(weakness, lack of energy and strength) for both arms. 
Children receiving ASAQ reported significantly more 
asthenia and anorexia (loss of appetite) than children 
receiving AL (Table 4).
Discussion
The results of this study indicate that both study drugs 
retain adequate efficacy (PCR corrected cure rate at 
day 42 of 94.7 % for ASAQ and 99.0 % for AL) in the 
treatment of uncomplicated P. falciparum malaria in 
children aged six to 59  months in the study setting. 
In 2004, a similar study in DRC (Pool Region) showed 
comparable results (98.5 % efficacy of ASAQ and 100 % 
efficacy of AL at 28 days) [21]. This was also the result 
of the efficacy study by Singana et al. [22] in Owando 
in Congo-Brazzaville done in 2012–2103 (efficacy of 
ASAQ 98.0 % and of AL 100.0 % at 28 days, after PCR 
correction). The 4ABC study group, performed in a 
comparable population and using the same methodol-
ogy, showed a similar efficacy rate between 2007 and 
2009 over seven sub-Saharan African countries (96.8 % 
efficacy of ASAQ and 95.5 % efficacy of AL at 28 days) 
[23]. In the 4ABC study, ASAQ was also shown to be 
effective in Eastern Africa, whereas other studies had 
previously casted doubts over its efficacy in this region 
[24, 25].
The high efficacy of both ASAQ and AL in this region 
is reassuring. WHO only recommends a switch in the 
first line treatment if the efficacy falls below 90  % [26]. 
Although this study confirms that both artemisinin-
based combinations retain good efficacy in this part of 
DRC, it does, however, demonstrate high re-infection 
levels. After PCR correction, this study showed that, 
over 6  weeks, 21/119 children (17.6  %) of those who 
were on ASAQ and 15/119 (12.6 %) of the children in the 
AL treatment group (p =  0.29) were re-infected within 
42 days.
Whilst re-infections do not indicate failing anti-malar-
ial drugs, they are of public health relevance and pose a 
considerable burden to the population and health sys-
tems. The results of this study seem to support recent 
findings that the period over which lumefantrine and 
amodiaquine provide post-treatment protection is 
10–14  days [26–28]. However, considering the public 
health impact of frequent malaria infections in infants, 
it would be useful to do further analysis into the specific 
protective period for each of ASAQ and AL in this set-
ting. It is also worth considering if the use of an ACT with 
a longer protective half-life, such as dihydroartemisinin–
piperaquine, may be beneficial to prevent malaria epi-
sodes in the study population, exposed to intense malaria 
transmission [27–29].
In this study’s setting children will normally receive 
ASAQ each time they have a malaria infection. Reas-
suringly, Yeka et al. [29] showed that repeated treatment 
using both ASAQ and AL is effective, safe and well-tol-
erated in children under 5  years of age and in a similar 
context [29].
Fig. 5 Kaplan–Meier survival estimates PCR-adjusted. Treatment 
efficacy for ASAQ and AL was 96.6 and 100 % at day 28 (p = 0.0406), 
and 94.7 and 99.0 % at day 42 (p = 0.0496), respectively
Table 3 Parasite clearance on Days 2 and 3 of treatment
ASAQ AL p value
Patients with parasite  
positivity at D2
18 (13.7 %) 27 (20.0 %) 0.173
Patients with parasite  
positivity at D3
2 (1.5 %) 6 (4.4 %) 0.167
Table 4 Adverse events = classified as related to the drug, 
for all patients during the study period
ASAQ  
(n = 144)
AL (n = 144) Total p value
Asthenia 61 (42.4 %) 13 (9.0 %) 74 (25.7 %) <0.001
Anorexia 27 (18.8 %) 12 (8.3 %) 39 (13.5 %) 0.010
Vomiting 11 (7.6 %) 10 (6.9 %) 21 (7.3 %) 0.821
Cough 5 (3.5 %) 7 (4.9 %) 12 (4.2 %) 0.555
Abdominal 
Pain
6 (4.2 %) 2 (1.4 %) 8 (2.8 %) 0.151
Diarrhoea 4 (2.8 %) 2 (1.4 %) 6 (2.1 %) 0.409
Itching 3 (2.1 %) 1 (0.7 %) 4 (1.4 %) 0.314
Nausea 1 (0.7 %) 1 (0.7 %) 2 (0.7 %) 1.000
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With regards to tolerability, there were no serious 
adverse events registered during the trial. Asthenia 
and anorexia were the most commonly recorded minor 
adverse events with a marked difference between the two 
drugs. It was shown by the results of this study that AL 
was better tolerated. During the study it was observed 
that the parents/caretakers would prefer that their child 
be randomized to AL rather than ASAQ as the former 
was perceived as more tolerable by the children. In fact, 
the chance to be randomized to receive AL seemed to be 
a major driving force to participate in the study. Although 
asthenia and anorexia may be classified as minor adverse 
effects, it can have a negative effect on adherence, and 
thus prevent a complete cure.
There was a relatively high proportion (67 %) of children 
excluded from the study at the time of screening. There 
were two major reasons for exclusion: the high number of 
children with co-morbidities, and the high number of chil-
dren who had taken ACT in the previous 28 days (either 
from a clinic or from a private vendor). In the children 
with co-morbidities, it is not clear what relation malaria 
had to their clinical illness; the children could be present-
ing with clinical illness due to malaria, or have symptoms 
primarily from their co-morbidity but happen to have 
malaria parasites. This is a dilemma that is faced often in 
the field, and may lead to an overestimation of the burden 
of malaria. Furthermore, an RDT for malaria is often per-
formed as a first means of triage for fever, and when the 
test is positive, there is the risk that the child may not be 
adequately examined for other illnesses. In this study, 49 
of the 873 (5.6 %) children with a positive RDT (based on 
HRP2 detection) had a negative thick smear. This could 
be the result of circulating HRP2 from a previous, well 
treated malaria infection. This is expected considering that 
Grandesso et  al. (internal communication, Clinical Trial.
gov Identifier NCT01325974) have shown that over 50 % 
of HRP2 RDTs remain positive more than 6  weeks after 
adequate treatment of a malaria infection.
Conclusion
ASAQ is still effective as a treatment for uncomplicated 
malaria in Baraka, South Kivu, DRC, 9  years after its 
introduction as a first-line treatment. There is no evi-
dence that ASAQ is inferior to AL in this setting with the 
non-inferiority margin of 7 % that was set for the current 
study. AL may have higher efficacy but additional trials 
are required to draw this conclusion with confidence. 
There is a high rate of re-infection in South-Kivu within 
six weeks of adequate treatment of either ASAQ or AL, 
indicating intense malaria transmission. AL was better 
tolerated by patients than ASAQ. Although earlier esti-
mates of anti-malarial drug efficacy are unavailable for 
the current population, the high efficacy of ASAQ makes 
it unlikely that declining drug efficacy is a reason for 
the apparent increase in malaria cases observed in the 
region.
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